Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Portal Hypertension Secondary to Myelofibrosis

A Study of Three Cases

Alvarez-Larrán, Alberto, M.D.1; Abraldes, Juan G., M.D.2; Cervantes, Francisco, M.D.1; Hernández-Guerra, Manuel, M.D.2; Vizzutti, Francesco, M.D.3; Miquel, Rosa, M.D.4; Gilabert, Rosa, M.D.5; Giusti, Massimo, M.D.6; Garcia-Pagan, Juan Carlos, M.D.2; Bosch, Jaime, M.D.2

American Journal of Gastroenterology: October 2005 - Volume 100 - Issue 10 - p 2355–2358

BACKGROUND In patients with idiopathic myelofibrosis (IM), portal hypertension (PHT) without thrombosis of the hepatic or splenoportal veins is infrequent.

OBJECTIVE To ascertain the mechanisms responsible for the development of PHT in IM and their therapeutic implications.

PATIENTS AND METHODS Color Doppler ultrasound with portal flow quantification, hepatic hemodynamic studies, and histological examinations of the liver biopsies were performed in three IM patients with PHT in whom hepatic and splenoportal thrombosis were ruled out.

RESULTS Two patients showed sinusoidal PHT (increased hepatic venous pressure gradient), normal portal flow, and massive myeloid metaplasia of the liver. Transjugular intrahepatic portosystemic shunt (TIPS) was indicated for variceal bleeding and ascites unresponsive to medical therapy, and resulted in an adequate control of these PHT complications. At the time of TIPS placement, direct portal pressure measurement showed a marked presinusoidal component in the PHT. A third patient died as a consequence of the IM before treatment of PHT could be instituted. This patient showed an extremely increased portal flow and lesser hepatic infiltration.

CONCLUSIONS IM patients with PHT might have a marked presinusoidal component contributing to PHT that is underestimated by hepatic vein catheterization. Treatment of the complications of PHT might not differ from that of patients with cirrhosis.

1Hematology Department, Azienda Ospedaliero Universitaria di Careggi, Firenze, Italy

2Hemodynamic Laboratory, Liver Unit, Azienda Ospedaliero Universitaria di Careggi, Firenze, Italy

3Dipartimento ad Attività Integrata Specialità Medico-Chirurgiche U.O. Malattie Epatiche ed Intestinali, Azienda Ospedaliero Universitaria di Careggi, Firenze, Italy

4Department of Pathology, Hospital Clínic, IDIBAPS, University of Barcelona, Spain

5Department of Radiodiagnostic, Hospital Clínic, IDIBAPS, University of Barcelona, Spain

6Sezione di Gastroenterologia Ospedale di Pistoia, Italy

Reprint requests and correspondence: Garcia-Pagan, Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain.

Received March 11, 2005; May 12, 2005.

© The American College of Gastroenterology 2005. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website